Which hepatitis B tests should be performed before initiating rituximab therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Pre-Rituximab Hepatitis B Testing

All patients must be screened with three serologic tests before initiating rituximab: HBsAg (hepatitis B surface antigen), anti-HBc (hepatitis B core antibody - total or IgG), and anti-HBs (hepatitis B surface antibody). 1

Required Screening Panel

The complete pre-rituximab HBV screening consists of:

  • HBsAg - identifies chronic/active HBV infection
  • Anti-HBc (total immunoglobulin or IgG) - identifies past or occult HBV exposure
  • Anti-HBs - identifies immunity from vaccination or resolved infection

1, 2

This three-test panel should be obtained within 90 days before rituximab initiation, though treatment should not be delayed while awaiting results 1.

Why All Three Tests Matter

Rituximab carries the highest risk of HBV reactivation among immunosuppressive agents, classified as a B-cell depleting therapy with high reactivation risk 2, 3. The comprehensive screening is critical because:

  • HBsAg-positive patients (chronic infection) require immediate antiviral prophylaxis regardless of HBV DNA levels
  • HBsAg-negative but anti-HBc-positive patients (resolved/occult infection) also require prophylaxis with rituximab - this is unique to anti-CD20 therapies and distinguishes rituximab from other immunosuppressants 1, 2
  • Anti-HBs positivity does NOT eliminate reactivation risk - recent case reports confirm HBV reactivation can occur despite positive anti-HBs 4

Critical Management Based on Results

If HBsAg-Positive (Chronic HBV):

  • Start antiviral prophylaxis with entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF) before or simultaneously with rituximab
  • Continue prophylaxis during treatment plus 12 months after the last rituximab dose (18 months for some regimens)
  • Avoid lamivudine due to resistance 1, 2

If HBsAg-Negative but Anti-HBc-Positive (Resolved/Occult HBV):

  • Start antiviral prophylaxis - this is mandatory for rituximab, unlike other immunosuppressants where monitoring may be acceptable
  • Use same agents (entecavir, TDF, or TAF) for same duration (12 months post-rituximab)
  • Alternative: Monitor HBsAg, ALT, and HBV DNA every 1-3 months, but prophylaxis is strongly preferred 1, 2

If All Tests Negative:

  • No prophylaxis needed
  • No routine monitoring required

Common Pitfalls to Avoid

Testing only HBsAg is insufficient - real-world data shows 27-47% of patients receive incomplete screening, missing occult infections 5, 6, 7. Studies document that patients with isolated anti-HBc positivity who don't receive prophylaxis have a 7.4% reactivation rate 8.

Don't assume anti-HBs provides protection - seroreversion (HBsAg becoming positive despite anti-HBs) has been documented with rituximab 4.

Reactivation can occur up to 24 months after the last rituximab dose 3, so prolonged monitoring (up to 2 years) is recommended even after completing antiviral prophylaxis 2.

The Evidence Strength

The 2020 ASCO guideline 1 represents the most recent high-quality guidance, consistently supported by multiple gastroenterology guidelines 2 and FDA labeling 3. Recent population-based studies 5, 6 confirm that despite these clear recommendations, screening adherence remains suboptimal (10-60% receive timely complete screening), and HBV reactivation—though preventable—continues to cause significant morbidity and mortality, including fatal liver decompensation.

The three-test panel is non-negotiable for rituximab because this agent uniquely requires prophylaxis even for resolved HBV infection, distinguishing it from nearly all other immunosuppressive therapies.

References

Related Questions

What infection screening tests and vaccinations should be completed before initiating rituximab therapy?
Is hepatitis B screening (HBsAg and anti‑HBc) required before initiating baricitinib therapy?
What are the risks of hepatotoxicity associated with rituximab and how should liver function be monitored and managed during therapy?
Which examinations should be performed before initiating rituximab therapy?
What management steps should be taken for CD4 count monitoring and viral load assessment in an HIV‑positive patient with a CD4 count of 163 cells/µL?
In a 66-year-old patient with known hypothyroidism who stopped levothyroxine 25 µg for two months, how should the elevated thyroid‑stimulating hormone (TSH) and low‑normal total thyroxine (T4) be interpreted?
What are the causes of direct (conjugated) hyperbilirubinemia during pregnancy?
Can a patient with chronic obstructive pulmonary disease (COPD) take doxofylline capsules daily?
What is the appropriate treatment for acute appendicitis and grade 2 fatty liver (moderate steatosis)?
In a COPD patient with pulmonary arterial hypertension presenting with hypercapnic respiratory failure (pH 7.43, PaO2 60 mm Hg, PaCO2 67 mm Hg, lactate 0.9 mmol/L, bicarbonate 44 mmol/L), what ventilator settings should be used?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.